Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mirjam Crul

Showing results (41-50 of 57) with videos related to

Pageof 6
Sort By:
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|June 27, 2025
Particulate contamination in parenteral fluid from glass ampoules: compliance assessment and comparative analysis of needle types and ampoule-breaking strategiesRoland B van den Berg, Elizabeth Serbée-Wijker, Elsbeth M Westerman, et al.
Cancer Chemotherapy and Pharmacology|November 27, 2002
Clinical pharmacokinetics, pharmacodynamics and metabolism of the novel matrix metalloproteinase inhibitor ABT-518Mirjam Crul, Laurens V Beerepoot, Ellen Stokvis, et al.
Anti-Cancer Drugs|September 16, 2005
Phase I clinical and pharmacologic study of a 2-weekly administration of cisplatin and gemcitabine in patients with advanced non-small cell lung cancerJeany M Rademaker-Lakhai, Mirjam Crul, Dick Pluim, et al.
Biochemical Pharmacology|December 31, 2002
DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatinMirjam Crul, Robert C A M van Waardenburg, Suzanne Bocxe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2006
Relationship between cisplatin administration and the development of ototoxicityJeany M Rademaker-Lakhai, Mirjam Crul, Lot Zuur, et al.
British Journal of Clinical Pharmacology|December 23, 2025
Model-informed precision dosing of carboplatin in cancer patients by leveraging myelosuppression data from electronic health recordsAlessandro De Carlo, Elena Maria Tosca, Mirjam Crul, et al.
Cancer Chemotherapy and Pharmacology|March 27, 2002
Population pharmacokinetics of the novel anticancer agent KRN7000Mirjam Crul, Ron A Mathôt, Giuseppe Giaccone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2003
Randomized phase I clinical and pharmacologic study of weekly versus twice-weekly dose-intensive cisplatin and gemcitabine in patients with advanced non-small cell lung cancerMirjam Crul, Nadja E Schoemaker, Dick Pluim, et al.
Journal of Occupational and Environmental Medicine|April 17, 2025
Occupational Exposure of Healthcare Workers during Drug Reconstitution and Handling Tasks: a multicenter assessment at Dutch Hospital WardsRoland B van den Berg, Percival Stubbs, Johanna R C Boumans-d'Onofrio, et al.
Oral Oncology|April 15, 2025
Comparison of cisplatin-induced hearing loss in different durations of infusion and volume of hydration schedules in head and neck squamous cell carcinoma patients treated with cisplatin-based chemoradiationAnouk V M Burger, Melissa A Koot, Dorieke E M van Balen, et al.
Pageof 6

Showing results (41-50 of 57) with videos related to

Sort By:
Pageof 6
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|June 27, 2025
Particulate contamination in parenteral fluid from glass ampoules: compliance assessment and comparative analysis of needle types and ampoule-breaking strategiesRoland B van den Berg, Elizabeth Serbée-Wijker, Elsbeth M Westerman, et al.
Cancer Chemotherapy and Pharmacology|November 27, 2002
Clinical pharmacokinetics, pharmacodynamics and metabolism of the novel matrix metalloproteinase inhibitor ABT-518Mirjam Crul, Laurens V Beerepoot, Ellen Stokvis, et al.
Anti-Cancer Drugs|September 16, 2005
Phase I clinical and pharmacologic study of a 2-weekly administration of cisplatin and gemcitabine in patients with advanced non-small cell lung cancerJeany M Rademaker-Lakhai, Mirjam Crul, Dick Pluim, et al.
Biochemical Pharmacology|December 31, 2002
DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatinMirjam Crul, Robert C A M van Waardenburg, Suzanne Bocxe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2006
Relationship between cisplatin administration and the development of ototoxicityJeany M Rademaker-Lakhai, Mirjam Crul, Lot Zuur, et al.
British Journal of Clinical Pharmacology|December 23, 2025
Model-informed precision dosing of carboplatin in cancer patients by leveraging myelosuppression data from electronic health recordsAlessandro De Carlo, Elena Maria Tosca, Mirjam Crul, et al.
Cancer Chemotherapy and Pharmacology|March 27, 2002
Population pharmacokinetics of the novel anticancer agent KRN7000Mirjam Crul, Ron A Mathôt, Giuseppe Giaccone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2003
Randomized phase I clinical and pharmacologic study of weekly versus twice-weekly dose-intensive cisplatin and gemcitabine in patients with advanced non-small cell lung cancerMirjam Crul, Nadja E Schoemaker, Dick Pluim, et al.
Journal of Occupational and Environmental Medicine|April 17, 2025
Occupational Exposure of Healthcare Workers during Drug Reconstitution and Handling Tasks: a multicenter assessment at Dutch Hospital WardsRoland B van den Berg, Percival Stubbs, Johanna R C Boumans-d'Onofrio, et al.
Oral Oncology|April 15, 2025
Comparison of cisplatin-induced hearing loss in different durations of infusion and volume of hydration schedules in head and neck squamous cell carcinoma patients treated with cisplatin-based chemoradiationAnouk V M Burger, Melissa A Koot, Dorieke E M van Balen, et al.
Pageof 6